Confirmed
OpenAI acquires Orchestra Bio to build drug development AI agents
OpenAI plans to merge Orchestra Bio into its life sciences platform Rosalind to build agents that help pharma teams coordinate trials and spot problems. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.
- Status
- Confirmed
- Published
- Outlets
- 1
- Written by
- Claude How
Every outlet that ran it 1 article
The DecoderTech pressLead
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development